


# Development of IKZF2 molecular glue degrader

Korea Research Institute of Chemical Technology

<b>Disease Area</b>	<b>Oncology</b>
<b>Product Type</b>	Molecular Glue Degradator (MGD)
<b>Indication</b>	Solid Tumor
<b>Target</b>	IKZF2 (Helios)
<b>Mechanism of Action</b>	Degradation of IKZF2 mediated by CRBN E3 ligase
<b>Competitiveness</b>	<ul style="list-style-type: none"> <li>• Best-in-Class</li> <li>• Highly potent and selective IKZF2 degrader</li> <li>• Very good PK and anti-tumor efficacy in syngeneic mouse model</li> <li>• Competitor : Plexium (PLX-4107, Phase I), BMS (Phase I), Novartis (DKY709, Phase I, Discontinued)</li> </ul>
<b>Development Stage</b>	<b>Lead</b>
<b>Route of Administration</b>	Oral (PO)

## Key Data



**Quantitative analysis (WB)**

Jurkat 6hr treatment	DC <sub>50</sub> (nM), [D <sub>max</sub> (%)]			
	IKZF2	IKZF1	IKZF3	GSPT1
<b>DKY709</b>	1640 [57]	56700 [37.6]	> 10000	> 10000
<b>KMG-1694</b>	0.19 [100]	21200 [41.6]	> 10000	> 10000

